Physician profile
Kasing Ho
NPI 1104864925
$5,590.70
in general payments reported to CMS, 2019-2025
40 companies · $625 in 2025
The $625 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $520 · 2021: $579 · 2022: $696 · 2023: $988 · 2024: $1,224 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,837.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $939.20 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $504.03 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.68 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Lilly USA, LLC | $394.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $386.29 | 2019-2023 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $336.84 | 2019-2024 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $311.85 | 2019-2025 | Capvaxive, Verquvo, Gardasil 9 |
| Pfizer INC. | $261.39 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $236.75 | 2023-2024 | Austedo Xr |
| Amgen INC. | $209.25 | 2019-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $155.58 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $111.18 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.85 | 2019-2023 | Jardiance, Synjardy |
| Collegium Pharmaceutical, INC. | $85.94 | 2022-2024 | Belbuca |
| Avanir Pharmaceuticals, INC. | $85.49 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $81.92 | 2019-2025 | |
| Lundbeck LLC | $76.69 | 2020-2025 | Rexulti |
| Mylan Specialty L.P. | $76.29 | 2022-2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $69.44 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $63.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $62.22 | 2020-2025 | Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $60.13 | 2021-2024 | Freestyle Libre |
| Exact Sciences Corporation | $60.05 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $53.37 | 2021-2022 | |
| Alk-Abello, INC | $45.08 | 2024 | Odactra, Grastek, Ragwitek |
| Allergan, INC. | $43.25 | 2020 | |
| Boston Scientific Corporation | $29.75 | 2024 | Emblem Mri S-Icd |
| Arbor Pharmaceuticals, INC. | $29.01 | 2021 | |
| Almatica Pharma LLC | $28.09 | 2022 | |
| Astellas Pharma US INC | $28.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $26.25 | 2020-2021 | |
| Cequr Corporation | $25.07 | 2022-2023 | Cequr Simplicity |
| Acadia Pharmaceuticals INC | $20.77 | 2020 | |
| Corcept Therapeutics | $17.30 | 2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $16.62 | 2024 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $14.97 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.46 | 2024 | Zilretta, Iovera |
| Xeris Pharmaceuticals, INC. | $14.29 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $12.57 | 2019 | |
| Sanofi Pasteur INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasing Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.